Lyell Immunopharma, Inc.

LYEL · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$39-$43-$52-$192
Dep. & Amort.$3$3$3$5
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$5$6$0
Change in WC-$0-$1-$10$0
Other Non-Cash$8$1-$2$140
Operating Cash Flow-$29-$34-$55-$47
Investing Activities
PP&E Inv.-$0-$0-$0-$0
Net Acquisitions$0$0$0-$31
Inv. Purchases-$71-$81-$84-$39
Inv. Sales/Matur.$74$94$154$124
Other Inv. Act.$0$0$0$0
Investing Cash Flow$3$13$69$54
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$50$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$0$0$0
Financing Cash Flow$50$0$0$0
Forex Effect-$0$0$0-$1
Net Chg. in Cash$25-$22$15$5
Supplemental Information
Beg. Cash$99$122$107$100
End Cash$124$100$122$106
Free Cash Flow-$29-$35-$55-$47
Lyell Immunopharma, Inc. (LYEL) Financial Statements & Key Stats | AlphaPilot